![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
Follicular lymphoma is one of the most common subtypes of non-Hodgkin lymphoma. These cancers affect the lymphatic system, a part of the body's immune system. Specifically, follicular lymphoma affects B-lymphocytes, a type of white blood cell.
Follicular lymphoma cells express CD47 to avoid detection by healthy immune cells, which are in charge of eliminating cancer cells.
ALX Oncology is developing a next-generation checkpoint inhibitor called evoparcept. It is designed to bind and block CD47 and avoid the side effects seen with other CD47-blocking therapies. When it binds to CD47, evorparcept helps signal the immune response against lymphoma cells.
Evorparcept is being studied in combination with rituximab and lenalidomide in a phase 1/2 trial that is currently enrolling patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Initial Results with Evorpacept in Follicular Lymphoma
Initial Results with Evorpacept in Follicular Lymphoma They treated 20 patients with NHL, of which 15 were follicular lymphoma patients. Researchers reported that adding evorpacept to the standard treatment (rituximab and lenalidomide) improved the number of responses compared to what is expected when treating with rituximab and lenalidomide alone.
After one year, 90% of patients treated with the triple combination are alive, and 70% are still in remission. Evoparcept has been considered to be well-tolerated, with the most common side effects being fatigue, low blood counts, and increased liver enzyme levels.
This clinical trial is ongoing, but it helped identify the optimal dose to move forward into a larger phase 2 study.
Expanding treatment options and enrolling in clinical trials for relapsed and refractory patients is crucial for finding a potential cure for all!
With our clinical trial finder within HealthTree Cure Hub, you can find up-to-date clinical trials recruiting patients in your area!
Sources:
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- A Phase I Investigator-initiated Trial of Evorpacept (ALX148), Lenalidomide and Rituximab for Patients with Relapsed or Refractory B-cell NHL, 2024 American Association for Cancer Research (“AACR”) Annual Meeting, Abstract #10285
Follicular lymphoma is one of the most common subtypes of non-Hodgkin lymphoma. These cancers affect the lymphatic system, a part of the body's immune system. Specifically, follicular lymphoma affects B-lymphocytes, a type of white blood cell.
Follicular lymphoma cells express CD47 to avoid detection by healthy immune cells, which are in charge of eliminating cancer cells.
ALX Oncology is developing a next-generation checkpoint inhibitor called evoparcept. It is designed to bind and block CD47 and avoid the side effects seen with other CD47-blocking therapies. When it binds to CD47, evorparcept helps signal the immune response against lymphoma cells.
Evorparcept is being studied in combination with rituximab and lenalidomide in a phase 1/2 trial that is currently enrolling patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Initial Results with Evorpacept in Follicular Lymphoma
Initial Results with Evorpacept in Follicular Lymphoma They treated 20 patients with NHL, of which 15 were follicular lymphoma patients. Researchers reported that adding evorpacept to the standard treatment (rituximab and lenalidomide) improved the number of responses compared to what is expected when treating with rituximab and lenalidomide alone.
After one year, 90% of patients treated with the triple combination are alive, and 70% are still in remission. Evoparcept has been considered to be well-tolerated, with the most common side effects being fatigue, low blood counts, and increased liver enzyme levels.
This clinical trial is ongoing, but it helped identify the optimal dose to move forward into a larger phase 2 study.
Expanding treatment options and enrolling in clinical trials for relapsed and refractory patients is crucial for finding a potential cure for all!
With our clinical trial finder within HealthTree Cure Hub, you can find up-to-date clinical trials recruiting patients in your area!
Sources:
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- A Phase I Investigator-initiated Trial of Evorpacept (ALX148), Lenalidomide and Rituximab for Patients with Relapsed or Refractory B-cell NHL, 2024 American Association for Cancer Research (“AACR”) Annual Meeting, Abstract #10285
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.